Subclinical and asymptomatic parathyroid disease: Implications of emerging data

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 4, 2013, Pages 329-340

  Macfarlane, David P ^a   Yu, Ning ^b   Leese, Graham P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PARATHYROID HORMONE;

BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CASR GENE; CAUSE OF DEATH; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; GENE; GENE MUTATION; HIP FRACTURE; HUMAN; KIDNEY CALCIFICATION; KIDNEY DISEASE; MENTAL DISEASE; MORBIDITY; NEPHROGENIC DIABETES INSIPIDUS; NEPHROLITHIASIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SPINE FRACTURE; THYROIDECTOMY; TREATMENT INDICATION; TREATMENT RESPONSE; ANIMAL; ASYMPTOMATIC DISEASES; FACTUAL DATABASE; HYPERPARATHYROIDISM; PARATHYROID DISEASES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRENDS;

ANIMALS; ASYMPTOMATIC DISEASES; DATABASES, FACTUAL; HUMANS; HYPERPARATHYROIDISM; PARATHYROID DISEASES; PARATHYROIDECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887624529     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70083-4     Document Type: Review

References (93)

1. Fraser WD Hyperparathyroidism. Lancet 2009, 374:145-158.
2. Egbuna OI, Brown EM Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 2008, 22:129-148.
3. Marcocci C, Cetani F Clinical practice. Primary hyperparathyroidism. N Engl J Med 2011, 365:2389-2397. 22.
4. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94:340-350.
5. Newey PJ, Nesbit MA, Rimmer AJ, et al. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab 2012, 97:E1995-E2005.
6. Hendy GN, Cole DE Genetic defects associated with familial and sporadic hyperparathyroidism. Front Horm Res 2013, 41:149-165.
7. Auwerx J, Demedts M, Bouillon R Altered parathyroid set point to calcium in familial hypocalciuric hypercalcaemia. Acta Endocrinol (Copenh) 1984, 106:215-218.
8. Pearce SH, Williamson C, Kifor O, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996, 335:1115-1122.
9. Bilezikian JP, Khan A, Potts JT, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 2011, 26:2317-2337.
10. Fraser WD, Milan AM Vitamin D assays: past and present debates, difficulties, and developments. Calcif Tissue Int 2013, 92:118-127.
11. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94:351-365.
12. Yu N, Leese GP, Smith D, Donnan PT The natural history of treated and untreated primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study. QJM 2011, 104:513-521.
13. Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997, 121:287-294.
14. Palmer M, Jakobsson S, Akerstrom G, Ljunghall S Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Invest 1988, 18:39-46.
15. Boonstra CE, Jackson CE Serum calcium survey for hyperparathyroidism: results in 50,000 clinic patients. Am J Clin Pathol 1971, 55:523-526.
16. Christensson T, Hellstrom K, Wengle B Blood pressure in subjects with hypercalcaemia and primary hyperparathyroidism detected in a health screening programme. Eur J Clin Invest 1977, 7:109-113.
17. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013, 98:1122-1129.
18. Abood A, Vestergaard P Increasing incidence of primary hyperparathyroidism in Denmark. Dan Med J 2013, 60:A4567.
19. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008, 93:3462-3470.
20. Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998, 104:115-122.
21. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007, 92:1687-1692.
22. Hedback G, Tisell LE, Bengtsson BA, Hedman I, Oden A Premature death in patients operated on for primary hyperparathyroidism. World J Surg 1990, 14:829-835.
23. Proceedings of the NIH Consensus Development Conference on diagnosis and management of asymptomatic primary hyperparathyroidism. Bethesda, Maryland, October 29-31, 1990. J Bone Miner Res 1991, 6:S1-166.
24. Bilezikian JP, Khan AA, Potts JT Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94:335-339.
25. Silverberg SJ, Brown I, Bilezikian JP Age as a criterion for surgery in primary hyperparathyroidism. Am J Med 2002, 113:681-684.
26. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341:1249-1255.
27. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988, 67:1294-1298.
28. Lundgren E, Lind L, Palmer M, Jakobsson S, Ljunghall S, Rastad J Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 2001, 130:978-985.
29. Rejnmark L, Vestergaard P, Mosekilde L Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 2011, 96:2377-2385.
30. Walker MD, Dempster DW, McMahon DJ, et al. Effect of renal function on skeletal health in primary hyperparathyroidism. J Clin Endocrinol Metab 2012, 97:1501-1507.
31. Yeh MW, Wiseman JE, Ituarte PH, et al. Surgery for primary hyperparathyroidism: are the consensus guidelines being followed?. Ann Surg 2012, 255:1179-1183.
32. Tassone F, Gianotti L, Emmolo I, Ghio M, Borretta G Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94:4458-4461.
33. Yu N, Donnan PT, Leese GP A record linkage study of outcomes in patients with mild primary hyperparathyroidism: The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2011, 75:169-176.
34. Starup-Linde J, Waldhauer E, Rolighed L, Mosekilde L, Vestergaard P Renal stones and calcifications in patients with primary hyperparathyroidism: associations with biochemical variables. Eur J Endocrinol 2012, 166:1093-1100.
35. Wishart J, Horowitz M, Need A, Nordin BE Relationship between forearm and vertebral mineral density in postmenopausal women with primary hyperparathyroidism. Arch Intern Med 1990, 150:1329-1331.
36. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. TR 843 1994, WHO, World Health Organisation, Geneva.
37. VanderWalde LH, Liu IL, Haigh PI Effect of bone mineral density and parathyroidectomy on fracture risk in primary hyperparathyroidism. World J Surg 2009, 33:406-411.
38. Rao DS, Phillips ER, Divine GW, Talpos GB Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004, 89:5415-5422.
39. Bollerslev J, Rosen T, Mollerup CL, et al. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94:2255-2261.
40. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007, 92:3114-3121.
41. Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res 2013, 28:1029-1040.
42. Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen K Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J Bone Miner Res 2012, 27:1150-1158.
43. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000, 321:598-602.
44. Vestergaard P, Mosekilde L Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003, 327:530-534.
45. Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94:2306-2312.
46. Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88:581-587.
47. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89:3319-3325.
48. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001, 16:113-119.
49. Sankaran S, Gamble G, Bolland M, Reid IR, Grey A Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 2010, 95:1653-1662.
50. Horiuchi T, Onouchi T, Inoue J, Shionoiri A, Hosoi T, Orimo H A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. Gerontology 2002, 48:103-108.
51. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90:135-141.
52. Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009, 94:4860-4867.
53. Kahal H, Aye M, Rigby AS, Sathyapalan T, England RJ, Atkin SL The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clin Endocrinol (Oxf) 2012, 76:196-200.
54. Eigelberger MS, Cheah WK, Ituarte PH, Streja L, Duh QY, Clark OH The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited?. Ann Surg 2004, 239:528-535.
55. Barkun J, Duh QY, Wiseman S Canadian Association of General Surgeons and American College of Surgeons evidence based reviews in surgery. 16. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism. Can J Surg 2006, 49:59-61.
56. Hedback G, Oden A Increased risk of death from primary hyperparathyroidism-an update. Eur J Clin Invest 1998, 28:271-276.
57. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A Clinical presentation of primary hyperparathyroidism in Europe-nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002, 17(suppl):N68-N74.
58. Soreide JA, van Heerden JA, Grant CS, Yau LC, Schleck C, Ilstrup DM Survival after surgical treatment for primary hyperparathyroidism. Surgery 1997, 122:1117-1123.
59. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003, 27:216-222.
60. Leifsson BG, Ahren B Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab 1996, 81:2149-2153.
61. Hagstrom E, Lundgren E, Lithell H, et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol (Oxf) 2002, 56:253-260.
62. Lundgren E, Ljunghall S, Akerstrom G, Hetta J, Mallmin H, Rastad J Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism. Surgery 1998, 124:980-985.
63. Taylor WH, Khaleeli AA Prevalence of primary hyperparathyroidism in patients with diabetes mellitus. Diabet Med 1997, 14:386-389.
64. Ahlstrom T, Hagstrom E, Larsson A, Rudberg C, Lind L, Hellman P Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women. Clin Endocrinol (Oxf) 2009, 71:673-678.
65. Lind L, Jacobsson S, Palmer M, Lithell H, Wengle B, Ljunghall S Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med 1991, 230:29-35.
66. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90:3326-3330.
67. Rubin MR, Rundek T, McMahon DJ, Lee HS, Sacco RL, Silverberg SJ Carotid artery plaque thickness is associated with increased serum calcium levels: the Northern Manhattan study. Atherosclerosis 2007, 194:426-432.
68. Farahnak P, Larfars G, Sten-Linder M, Nilsson IL Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J Clin Endocrinol Metab 2011, 96:2112-2118.
69. Luigi P, Chiara FM, Laura Z, et al. Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. Int J Endocrinol 2012, 2012:408295.
70. Stefenelli T, Mayr H, Bergler-Klein J, Globits S, Woloszczuk W, Niederle B Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993, 95:197-202.
71. Persson A, Bollerslev J, Rosen T, et al. Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism. Clin Endocrinol (Oxf) 2011, 74:174-180.
72. Walker MD, Rundek T, Homma S, et al. Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur J Endocrinol 2012, 167:277-285.
73. Nilsson IL, Zedenius J, Yin L, Ekbom A The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocr Relat Cancer 2007, 14:135-140.
74. Palmer M, Adami HO, Bergstrom R, Akerstrom G, Ljunghall S Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987, 102:1-7.
75. Hedback G, Oden A, Tisell LE The influence of surgery on the risk of death in patients with primary hyperparathyroidism. World J Surg 1991, 15:399-405.
76. Hedback GM, Oden AS Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med 2002, 2516:476-483.
77. Grey A Nonsurgical management of mild primary hyperparathyroidism - a reasonable option. Clin Endocrinol (Oxf) 2012, 77:639-644.
78. Yu N, Leese GP, Donnan PT What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2013, 79:27-34.
79. D'Agostino RB, Grundy S, Sullivan LM, Wilson P Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.
80. Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94:3849-3856.
81. Hagstrom E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009, 119:2765-2771.
82. Cusano NE, Maalouf NM, Wang PY, et al. Normocalcaemic hyperparathyroidism and hypoparathyroidism in two community-based non-referral populations. J Clin Endocrinol Metab 2013, 98:2734-2741.
83. Souberbielle JC, Bienaime F, Cavalier E, Cormier C Vitamin D and primary hyperparathyroidism (primary hyperparathyroidism). Ann Endocrinol (Paris) 2012, 73:165-169.
84. Rejnmark L, Amstrup AK, Mollerup CL, Heickendorff L, Mosekilde L Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study. J Clin Endocrinol Metab 2013, 98:87-96.
85. Rejnmark L, Vestergaard P, Brot C, Mosekilde L Increased fracture risk in normocalcaemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int 2011, 88:238-245.
86. Tordjman KM, Yaron M, Izkhakov E, et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcaemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol 2010, 162:925-933.
87. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ Normocalcaemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007, 92:3001-3005.
88. Al-Azem H, Khan AA Hypoparathyroidism. Best Pract Res Clin Endocrinol Metab 2012, 26:517-522.
89. Mishra A, Wong L, Jonklaas J Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine 2001, 14:159-164.
90. Comlekci A, Biberoglu S, Hekimsoy Z, et al. Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. Intern Med 1998, 37:396-397.
91. Even L, Bader T, Hochberg Z Nocturnal calcium, phosphorus and parathyroid hormone in the diagnosis of concealed and subclinical hypoparathyroidism. Eur J Endocrinol 2007, 156:113-116.
92. Bellamy RJ, Kendall-Taylor P Unrecognized hypocalcaemia diagnosed 36 years after thyroidectomy. J R Soc Med 1995, 88:690-691.
93. Selby P Asymptomatic primary hyperparathyroidism - we have half the answers. Clin Endocrinol (Oxf) 2011, 75:156-157.